Anti-VEGFR, PDGFR, and CSF1R tyrosine kinase inhibitor CM082 (X-82) in combination with everolimus for treatment of metastatic renal cell carcinoma: a phase 1 clinical trial
Authors:
- Xieqiao YanXYXieqiao Yan
- Xinan ShengXSXinan Sheng
- Bixia TangBTBixia Tang
- Zhihong ChiZCZhihong Chi
- Chuanliang CuiCCChuanliang Cui
- Lu SiLSLu Si
- Li Li MaoLMLi Li Mao
- Bin LianBLBin Lian
- Siming LiSLSiming Li
- Li ZhouLZLi Zhou
- Xuan WangXWXuan Wang
- Xue BaiXBXue Bai
- 1 September 2017
- journal article
- Published by Elsevier in The Lancet Oncology
- Vol. 18, S8